June 26, 2017 |
Washington, D.C. - June 26, 2017 - The COPD Foundation today announced the launch of the COPD and Pneumonia Study (CAP), a research initiative designed to describe the burden of pneumonia on individuals living with chronic obstructive pulmonary disease (COPD). COPD, a progressive lung disease characterized by wheezing and breathlessness, affects 30 million Americans. An acute lung infection, such as pneumonia, is potentially fatal for those living with COPD. The CAP study is designed to provide the scientific community with evidence of pneumonia’s impact from the perspective of affected patients.
The CAP study is a multi-stakeholder project comprised of a series of online surveys. The project will expand upon past studies measuring the impact of pneumonia on the general population, but have not specifically observed high risk populations such as those living with COPD. It will address these limitations by utilizing a patient-reported outcomes instrument called CAP-Burden of Illness Questionnaire (CAP-BIQ) as the baseline and for the longitudinal components.
June 14, 2017 |
WASHINGTON, D.C. - June 14, 2017 - The COPD Foundation announced today a grant award from Insmed, Inc. to expand the Bronchiectasis and NTM Research Registry. The Registry is a consolidated database of non-cystic fibrosis Bronchiectasis (NCFB) and/or Nontuberculous Mycobacterium (NTM) patients from multiple clinical institutions across the United States. The goal of the Registry is to support collaborative research and assist in the planning of clinical trials for the treatment of non-CF Bronchiectasis and/or NTM lung disease. Expansion plans include enrollment of 1,200 new patients into the Registry and the addition of at least two new Consortium sites.
May 22, 2017 |
Washington, D.C. - May 22, 2017 - The National Institutes of Health in a collaborative effort with representatives from across the entire COPD community released the COPD National Action Plan. This first-of-its-kind document provides a unified framework to guide stakeholders nationwide in their efforts to work together to positively impact the effect of the disease
The COPD National Action Plan follows the COPD Town Hall held in 2016 where patients, caregivers, government representatives, and medical professionals convened to address the disparities in government funding of prevention, treatment, and research around chronic obstructive pulmonary disease (COPD). The COPD Foundation has long advocated for the need to create a comprehensive Action Plan to tackle the national epidemic. COPD is a lung disease characterized by an increasing inability to breathe and is the third leading cause of death in the U.S.
May 17, 2017 |
WASHINGTON, D.C. - May 17, 2017 - Regional air quality organization Clean Air Partners celebrated 20 years of dedication to improving the greater Baltimore-Washington region’s air quality at last night’s Annual Awards Celebration. Clean Air Partners has reinvigorated the celebration with the Best In Air Awards, honoring industry leaders COPD Foundation, Grid Alternatives, and Lyft for their exemplary commitment to decreasing air pollution and protecting public health. The Awards also recognized middle and high school students for their outstanding creativity as part of the On the Air education awards. The full list of Award winners can be found at www.cleanairpartners.net.
“This is a celebratory year for Clean Air Partners – you don’t turn 20 twice," says Jennifer Desimone of Clean Air Partners. “We wanted to take it up a notch and commend organizations and companies for their commitment to improving our region’s air quality and protecting the health of our residents. We nominated nearly 20 organizations and opened it up to public voting – we are honored to have the support from the incredible winners.”
The Most Valuable Partner (MVP) Award recognizes an organization that has made significant efforts to promote everyday actions to reduce air pollution and the impacts they have on climate change and public health. After a four week public voting period, the COPD Foundation secured the most votes in the MVP category.
April 26, 2017 |
Washington, D.C. - April 26, 2017 - The COPD Foundation and American Lung Association today announced a partnership to help more patients living with chronic obstructive pulmonary disease (COPD) access clinical trials, and as a result enhance COPD research and outcomes.
The nation’s third leading cause of death, COPD is a condition that encompasses emphysema, chronic bronchitis, and other diseases characterized by increased breathlessness and wheezing. Through the coordination of the COPD Foundation’s COPD Patient-Powered Research Network (COPD PPRN) and the Lung Association’s Airways Clinical Research Centers (ACRC), both organizations are aiming to improve the quality of life for those living with disease.
The COPD Patient-Powered Research Network (COPD PPRN) is comprised of patients who have provided health and quality of life information using a robust technological infrastructure that supports clinical studies and surveys. The platform provides a unique opportunity for researchers to connect directly with participants, and is overseen by a patient-led governing board to ensure that patient priorities remain at the forefront.
March 22, 2017 |
WASHINGTON, D.C. - March 22, 2017 - The COPD Foundation is proud to announce the establishment of the JW Walsh Fund to Cure COPD in honor of our late founder and director emeritus, John W. Walsh. John recently passed away on March 7, 2017. The memorial fund was created as a way to honor John’s commitment to the mission of the Foundation which strives to find a cure for chronic obstructive pulmonary disease (COPD), the third leading cause of death within the United States.
John’s family has requested that donations in his memory be made to the JW Walsh Fund to Cure COPD, which will be administered by the Foundation.
John’s voice changed the way research studies are designed and executed, the way industry views the patient voice, and even changed the way patients are integrated into medical education. John dedicated much of his life to his commitment to speeding the development of new therapies and a cure for COPD. The COPD Foundation remains strongly committed to furthering John’s passion to engage, educate, and empower patients, helping to improve their lives as it searches for a cure.
March 07, 2017 |
The COPD Foundation is deeply saddened to announce that Founder and Director Emeritus John W. Walsh passed away today surrounded by his loving family.
John was an inspirational leader who lived each day pushing himself to advocate for those who did not have a voice and the world is a better place because of it.
John has touched the lives of countless individuals through his pioneering efforts in the respiratory field and his dedication to improving health, promoting worldwide detection and finding a cure for chronic obstructive pulmonary disease.
Our hearts go out to his wife Diane, daughter Linda, granddaughter Lily and extended family. We at the Foundation will continue to honor John by relentlessly pursuing his vision and continuing the work he so wholeheartedly embraced.
To share your stories or memories of John, please go to The John Walsh Memorial Page.
February 15, 2017 |
The COPD Foundation’s Board of Directors announced today that John W. Walsh, founder of the COPD Foundation, has retired from the COPD Foundation so that he may focus on his recovery from an injury that he incurred last year.
The Foundation’s Board elected John as its first Director Emeritus in recognition of his extraordinary service to the Foundation, and his profound commitment to improving the lives of those affected by chronic obstructive pulmonary disease (COPD).
“I am honored to have worked closely with John over the past two decades to advocate for the 30 million Americans with COPD. John’s tireless commitment to the COPD community and his unabashed enthusiasm for being ‘an impatient patient’ continues to inspire me and the work we do at the Foundation” said Byron Thomashow, MD, Chairman of the Board of Directors of the COPD Foundation.
January 10, 2017 |
WASHINGTON, D.C./MINNEAPOLIS, MN - January 11, 2017 -The COPD Foundation-sponsored COPD Biomarker Qualification Consortium (CBQC) today announced that it has partnered with the Bio-Techne Corporation, a manufacturer of biotechnology products for life science research and diagnostics. The partnership was established to evaluate the suitability of a soluble form of receptor for advanced glycation end products (sRAGE) as a predictive biomarker to support subject selection for clinical trials in emphysema. Increasing evidence suggests that serum sRAGE could serve as an indicator of the presence and/or progression of emphysema, a form of chronic obstructive disease (COPD). A validated commercial assay or test for sRAGE does not currently exist. The COPD Foundation, along with its partners in the CBQC and Bio-Techne, will be collaborating with a working group of industry and academic affiliates on the initiative.
“We are honored that the CBQC has chosen Bio-Techne as their development partner for this important test,” said Charles R. Kummeth, President and Chief Executive Officer of Bio-Techne. “We have a long history of innovation with different immunoassay technologies and biomarkers that can be applied here to ultimately help improve outcomes for emphysema patients.”
Since its inception in 2010, the CBQC has selected several important measures to be considered for qualification by the U.S. Food and Drug Administration (FDA) as tools for drug development. The initial measures/biomarkers selected were plasma fibrinogen (a blood biomarker), the St. George’s Respiratory Questionnaire, and the 6-minute walk test (an exercise test). Since serum and plasma sRAGE levels can prospectively identify the subset of patients with COPD at greatest risk for emphysema progression, targeted drug/biologic development and treatments could be optimized by using sRAGE measurements. Several large cohort studies have reported sRAGE to be a strong marker of emphysema, even more so than airflow obstruction.
December 09, 2016 |
WASHINGTON, D.C. - December 9, 2016 - The COPD Foundation, a nonprofit organization dedicated to curing chronic obstructive pulmonary disease (COPD), hosted its 2016 annual Air Affair Benefit, Thursday, Dec. 8, 2016, at the American Museum of Natural History in New York City. Dr. Byron Thomashow chaired the event as the Foundation paid tribute to a special group of individuals and organizations who were recognized for their contributions to the COPD community over the past year.
The gala evening featured country music artist Billy Dawson, famous for his songs Lance Corporal Austin and Whatever Happens. There was a special performance from Emmy Rose Russel the granddaughter of country icon Loretta Lynn. Emmy represented the Lynn family in memory of her aunt and Loretta’s daughter Betty Sue Lynn who passed away from COPD.
The COPD Foundation was pleased to announce the 2016 Air Affair Benefit awardees for their commitment to COPD awareness and the advancement of a COPD cure. Their advocacy, research, outreach, and care-delivery efforts have helped to build a broad understanding of the disease and support the Foundation improving lives for individuals with the disease. John W. Walsh, co-founder of the COPD Foundation, received the highest honor for his achievements in the COPD space.
November 14, 2016 |
WASHINGTON, D.C. - November 14, 2016 - The COPD Foundation, a non-profit organization dedicated to finding a cure for chronic obstructive pulmonary disease (COPD), today brings supporters the ability to donate with Apple Pay. COPD is the third leading cause of death in the U.S. and affects 30 million Americans. The progressive lung disease is characterized by increased breathlessness, coughing, and wheezing.
The COPD Foundation relies on the support of its membership to implement its research, education, and advocacy initiatives. Apple Pay will allow COPD Foundation supporters with the option of a more efficient and secure online financial transaction, making it easier for members to help the organization’s mission to help those affected by COPD.
Security and privacy is at the core of Apple Pay. When you use a credit or debit card with Apple Pay, the actual card numbers are not stored on the device, nor on Apple servers. Instead, a unique Device Account Number is assigned, encrypted and securely stored in the Secure Element on your device. Each transaction is authorized with a one-time unique dynamic security code.
Donating in apps and on websites accepting Apple Pay is as simple as the touch of a finger with Touch ID, so there’s no need to manually fill out lengthy account forms or repeatedly type in shipping and billing information.
November 08, 2016 |
MADISON, WI - Nov. 8, 2016 - Propeller Health, the leading digital solution for respiratory medicine, today announced U.S. Food and Drug Administration 510(k) clearance to market its Propeller platform for use with GSK's Ellipta® inhaler, the pharmaceutical company's innovative, patented, dry powder inhaler (DPI). The sensor for the Ellipta inhaler was built and cleared as part of a development agreement and R&D collaboration between Propeller and GSK that was announced on December 1, 2015.
"Today, we are pleased to announce the FDA clearance of the Propeller platform for use with GSK's Ellipta inhaler," said David Van Sickle, CEO and co-founder of Propeller. "Inclusion of GSK's Ellipta inhaler in Propeller's digitally-guided therapy platform is an important step in our goal of modernizing the management of respiratory disease. We look forward to working closely with GSK to deploy sensors for the Ellipta inhaler in the U.S. and abroad, in the near term."
Read the full press release here.